Behavioral profiles of mouse models for autism spectrum disorders.

Ey et al. (2011) read every paper on mice bred to show autism-like traits. They listed which mutants did what: some avoided new friends, some groomed until their fur fell out, some froze when the room got noisy. The team then asked: if we give these adult mice drugs or genes that fix the glitch, do the behaviors go away?

Even when treatment started long after mouse puberty, several strains still improved. Social mice began sniffing new roommates. Over-groomers calmed their paws. The authors warn the data are early, but the adult brain kept some plasticity.

Minshew et al. (2011) wrote a companion piece the same year. They agree mouse data are useful, yet stress we must watch timing: peer play right after weaning gives the biggest social lift. The two papers look opposite—adult fix vs early window—but they study different treatments. Elodie pools gene and drug studies in grown mice; Nancy zooms in on brief social enrichment in babies. Both can be true.

Laugeson et al. (2014) later tested one drug class in BTBR mice, the same strain Elodie flagged. Blocking one serotonin receptor sharpened reversal learning without the sluggish side-effects risperidone caused. Their positive result supports Elodie’s hope: adult pharmacology can tweak core ASD circuits.

Zhao et al. (2018) moved the question to monkeys, showing the field has outgrown mice. The monkey brain is closer to ours, but the ethical bar is higher. Together the reviews build a bridge: mouse proof-of-concept first, primate translation next.

You can tell families that biology keeps some doors open past early childhood. Mouse data say adult intervention is worth testing, even if early life remains the golden window. When you pick targets for teens or adults, look at the drug-gene pairs that reversed social or repetitive phenotypes in these reviews. Pair that with your behavioral plan—skills training plus biological support may pack more punch than either alone.